PortalPublikationenThe EBMT activity survey on hematopoietic-cell transplantati...

The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus

Standard

The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus. / Passweg, Jakob R; Baldomero, Helen; Chabannon, Christian; Basak, Grzegorz W; Corbacioglu, Selim; Duarte, Rafael; Dolstra, Harry; Lankester, Arjan C; Mohty, Mohamad; Montoto, Silvia; Peffault de Latour, Régis; Snowden, John A; Styczynski, Jan; Yakoub-Agha, Ibrahim; Kröger, Nicolaus; European Society for Blood and Marrow Transplantation (EBMT).

in: BONE MARROW TRANSPL, Jahrgang 55, Nr. 8, 08.2020, S. 1604-1613.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Passweg, JR, Baldomero, H, Chabannon, C, Basak, GW, Corbacioglu, S, Duarte, R, Dolstra, H, Lankester, AC, Mohty, M, Montoto, S, Peffault de Latour, R, Snowden, JA, Styczynski, J, Yakoub-Agha, I, Kröger, N & European Society for Blood and Marrow Transplantation (EBMT) 2020, 'The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus', BONE MARROW TRANSPL, Jg. 55, Nr. 8, S. 1604-1613. https://doi.org/10.1038/s41409-020-0826-4

APA

Passweg, J. R., Baldomero, H., Chabannon, C., Basak, G. W., Corbacioglu, S., Duarte, R., Dolstra, H., Lankester, A. C., Mohty, M., Montoto, S., Peffault de Latour, R., Snowden, J. A., Styczynski, J., Yakoub-Agha, I., Kröger, N., & European Society for Blood and Marrow Transplantation (EBMT) (2020). The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus. BONE MARROW TRANSPL, 55(8), 1604-1613. https://doi.org/10.1038/s41409-020-0826-4

Vancouver

Passweg JR, Baldomero H, Chabannon C, Basak GW, Corbacioglu S, Duarte R et al. The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus. BONE MARROW TRANSPL. 2020 Aug;55(8):1604-1613. https://doi.org/10.1038/s41409-020-0826-4

Bibtex

@article{de47e8ad14414a9c8fe9b8a312ffd084,
title = "The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus",
abstract = "Hematopoietic-cell transplantation (HCT) is widely used for acquired and congenital disorders of the hematopoietic system. Number of transplants performed in Europe and associated countries continues to rise with 47,468 HCT in 42,901 patients [19,630 allogeneic (41%) and 27,838 autologous (59%)] reported by 701 centers in 50 countries in 2018. Main indications were myeloid malignancies 10,679 (25%; 97% allogeneic), lymphoid malignancies 27,318 (64%; 20% allogeneic), solid tumors 1625 (4%; 2.9% allogeneic), and nonmalignant disorders 3063 (7%; 81% allogeneic). This year's analysis focuses on cellular therapies with the marked growth in CAR T-cell therapies from 151 in 2017 to 301 patients reported in 2018. Other cellular therapy numbers show less significant changes. Important trends in HCT include a 49% increase in allogeneic HCT for chronic phase CML (although transplant numbers remain low) and a 24% increase in aplastic anemia. In autologous HCT, there is an ongoing increase in autoimmune diseases (by 19%), predominantly due to activity in multiple sclerosis. This annual report reflects current activity and highlights important trends, useful for health care planning.",
author = "Passweg, {Jakob R} and Helen Baldomero and Christian Chabannon and Basak, {Grzegorz W} and Selim Corbacioglu and Rafael Duarte and Harry Dolstra and Lankester, {Arjan C} and Mohamad Mohty and Silvia Montoto and {Peffault de Latour}, R{\'e}gis and Snowden, {John A} and Jan Styczynski and Ibrahim Yakoub-Agha and Nicolaus Kr{\"o}ger and {European Society for Blood and Marrow Transplantation (EBMT)}",
year = "2020",
month = aug,
doi = "10.1038/s41409-020-0826-4",
language = "English",
volume = "55",
pages = "1604--1613",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "8",

}

RIS

TY - JOUR

T1 - The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus

AU - Passweg, Jakob R

AU - Baldomero, Helen

AU - Chabannon, Christian

AU - Basak, Grzegorz W

AU - Corbacioglu, Selim

AU - Duarte, Rafael

AU - Dolstra, Harry

AU - Lankester, Arjan C

AU - Mohty, Mohamad

AU - Montoto, Silvia

AU - Peffault de Latour, Régis

AU - Snowden, John A

AU - Styczynski, Jan

AU - Yakoub-Agha, Ibrahim

AU - Kröger, Nicolaus

AU - European Society for Blood and Marrow Transplantation (EBMT)

PY - 2020/8

Y1 - 2020/8

N2 - Hematopoietic-cell transplantation (HCT) is widely used for acquired and congenital disorders of the hematopoietic system. Number of transplants performed in Europe and associated countries continues to rise with 47,468 HCT in 42,901 patients [19,630 allogeneic (41%) and 27,838 autologous (59%)] reported by 701 centers in 50 countries in 2018. Main indications were myeloid malignancies 10,679 (25%; 97% allogeneic), lymphoid malignancies 27,318 (64%; 20% allogeneic), solid tumors 1625 (4%; 2.9% allogeneic), and nonmalignant disorders 3063 (7%; 81% allogeneic). This year's analysis focuses on cellular therapies with the marked growth in CAR T-cell therapies from 151 in 2017 to 301 patients reported in 2018. Other cellular therapy numbers show less significant changes. Important trends in HCT include a 49% increase in allogeneic HCT for chronic phase CML (although transplant numbers remain low) and a 24% increase in aplastic anemia. In autologous HCT, there is an ongoing increase in autoimmune diseases (by 19%), predominantly due to activity in multiple sclerosis. This annual report reflects current activity and highlights important trends, useful for health care planning.

AB - Hematopoietic-cell transplantation (HCT) is widely used for acquired and congenital disorders of the hematopoietic system. Number of transplants performed in Europe and associated countries continues to rise with 47,468 HCT in 42,901 patients [19,630 allogeneic (41%) and 27,838 autologous (59%)] reported by 701 centers in 50 countries in 2018. Main indications were myeloid malignancies 10,679 (25%; 97% allogeneic), lymphoid malignancies 27,318 (64%; 20% allogeneic), solid tumors 1625 (4%; 2.9% allogeneic), and nonmalignant disorders 3063 (7%; 81% allogeneic). This year's analysis focuses on cellular therapies with the marked growth in CAR T-cell therapies from 151 in 2017 to 301 patients reported in 2018. Other cellular therapy numbers show less significant changes. Important trends in HCT include a 49% increase in allogeneic HCT for chronic phase CML (although transplant numbers remain low) and a 24% increase in aplastic anemia. In autologous HCT, there is an ongoing increase in autoimmune diseases (by 19%), predominantly due to activity in multiple sclerosis. This annual report reflects current activity and highlights important trends, useful for health care planning.

U2 - 10.1038/s41409-020-0826-4

DO - 10.1038/s41409-020-0826-4

M3 - SCORING: Journal article

C2 - 32066864

VL - 55

SP - 1604

EP - 1613

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 8

ER -